QRG Capital Management Inc. Sells 19,045 Shares of Novo Nordisk A/S $NVO

QRG Capital Management Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 14.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 110,286 shares of the company’s stock after selling 19,045 shares during the quarter. QRG Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $5,611,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Quotient Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after purchasing an additional 177 shares during the last quarter. Certuity LLC grew its position in Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares during the period. Oakworth Capital Inc. raised its stake in Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after buying an additional 182 shares during the last quarter. True North Advisors LLC raised its stake in Novo Nordisk A/S by 3.9% during the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares during the last quarter. Finally, Revolve Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q1 beat and guidance raise driven by Wegovy pill: Management reported stronger‑than‑expected demand for the new Wegovy oral pill, lifted sales and raised FY‑2026 guidance, prompting the stock rally. Reuters: Q1 profit beats
• Positive Sentiment: Wegovy uptake scale: Total Wegovy prescriptions surpassed ~2 million since launch, indicating strong volume growth and potential to offset near‑term pricing headwinds. WSJ: Wegovy lifts guidance
• Positive Sentiment: Management open to M&A and broader pipeline build: CEO Mike Doustdar said Novo is actively seeking deals to strengthen its pipeline, which investors view as a sign management is pursuing growth options beyond organic product rollouts. CNBC: CEO on deals
• Positive Sentiment: Share repurchase program in place: Novo has an active share buyback program (part of a DKK15bn program) which supports per‑share metrics and can provide buy‑side demand. GlobeNewswire: Buyback
• Neutral Sentiment: Mixed analyst reads: Some analysts call the quarter an inflection/turnaround (beat + volume), others note mixed metrics and are cautious; the market is debating whether current pessimism already prices future upside. Seeking Alpha: Mixed Q1
• Negative Sentiment: Pricing pressure, margin compression and accounting noise: U.S. pricing pressure and a one‑off 340B benefit exclusion reduced adjusted EPS/revenue in the quarter and led management to give cautious near‑term guidance despite strong volumes. Seeking Alpha: Misread Q1
• Negative Sentiment: Intense competitive risk: A price war with Eli Lilly and potential generics (though China generic Ozempic may be delayed) remain major downside risks to pricing and long‑term margins. Reuters: Price war test

Analysts Set New Price Targets

Several analysts recently commented on NVO shares. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Wolfe Research started coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Trading Up 2.1%

Shares of NVO stock opened at $45.82 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company has a market cap of $204.57 billion, a price-to-earnings ratio of 13.20, a PEG ratio of 10.65 and a beta of 0.77. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The firm has a fifty day moving average price of $38.57 and a 200-day moving average price of $47.03.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.34 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.